Tert-Butyl(2S)-4-Oxo-2-(1,3-Thiazolidin-3-Yl Carbonyl) Pyrrolidine-1-Carboxylate

In the convergent synthesis of oral Factor Xa inhibitors, this bicyclic dipeptide isostere functions as a sterically constrained P1/P2 surrogate, replacing linear homophenylalanine analogues to reduce conformational entropy penalties at the S1 pocket. The fragment is introduced via EDCI·HCl-mediated coupling to a pre-formed 4-chlorobenzoyl-aminobenzamidine hydrochloride salt in anhydrous 2-MeTHF at −20 °C to −15 °C, with 1.08–1.12 eq of the pyrrolidine-thiazolidine building block relative to the benzamidine scaffold. Post-coupling, aqueous work-up at pH 5.8 strips dicyclohexylurea while retaining the acid-labile Boc group. Batch records from 50 L Hastelloy C22 reactors document a critical exotherm during EDCI dissolution; the dosing rate of the coupling agent solution is capped at 0.15 eq/min to contain ΔT ≤ 4 °C. Regulatory compliance follows ICH Q11 regarding starting material specification rigor: the building block must carry an enantiomeric excess ≥ 99.85 % by chiral SFC (CSP-H column, 30 % MeOH/CO₂, 3 mL/min, 220 nm), with (R)-enantiomer capped at 0.15 %. Residual 1,3-thiazolidine, a sulfur-containing primary amine classified as a potential mutagenic impurity per ICH M7 Class 2, is controlled below 15 ppm by headspace GC-MS (DB-624UI, 30 m×0.25 mm×1.4 μm). Elemental impurities are tested per USP<232>/<233> with Pd limit <10 μg/g and Ni limit <25 μg/g. The protected intermediate is crystallized from MeOH/water 4:1 v/v at 5 °C to achieve a final purity of 99.5 area% (HPLC, 254 nm) before advancing to the global deprotection step.

Subsequent hydrogenolysis of the benzamidine Cbz group over 5 % Pd/C (Johnson Matthey type 39, half-wet) in EtOAc/MeOH 1:1 at 1.5 bar H₂ and 35 °C yields the free amidine, which is telescoped directly into Boc cleavage with 4M HCl in dioxane at 20 °C. The terminal API salt form is typically an L-malate co-crystal. The targeted final dosage forms are 25 mg, 40 mg, and 80 mg immediate-release tablets, wherein the Factor Xa inhibitor content ranges from 10.5 % to 28.0 % w/w of the tablet core.

Are Residual Thiazolidine Solvates Driving OOS Results in NS3 Protease Intermediate Crystallization?

In the manufacture of macrocyclic hepatitis C NS3/4A protease inhibitors, the tert-butyl (2S)-4-oxo-2-(1,3-thiazolidine-3-carbonyl)pyrrolidine-1-carboxylate fragment is incorporated as a rigidified hydroxylamine isostere that engages the catalytic serine through a reversible covalent bond. The fragment is loaded onto a preformed cyclopropyl-acylsulfonamide tetrapeptide using HATU/HOAt in DMF at 0 °C with 2.5 eq DIPEA, at a stoichiometric ratio of 1.00 eq fragment to 1.00 eq core peptide; excess fragment above 1.02 eq leads to a difficult-to-purge diastereomeric adduct that co-elutes with the desired product on Kromasil 10 μm C18 preparative HPLC (acetonitrile/0.2 % aqueous TFA, 220 mL/min). After quenching with 0.1 N HCl and phase separation into IPAc, the organic phase is concentrated under vacuum and chased with toluene three times. The critical quality hazard emerges during solvent displacement: residual thiazolidine starting material — a decomposition byproduct of the fragment generated during extended storage above 25 °C — forms a crystalline solvate with the Boc-protected intermediate that precipitates in heptane/IPAc 8:1 v/v at −5 °C. DSC thermograms of this solvate show an endotherm at 113 °C that overlaps with the API intermediate melting range, eluding routine purity checks. To meet ICH M7 limits, the fragment supplier must provide a thiazolidine content <500 ppm and a shipping/storage condition of 2–8 °C under argon. The terminal product, after acidolysis of the Boc group and sulfonamide coupling, is a potent pan-genotypic NS3 inhibitor progressing to Phase II; the intended drug product format is a 100 mg film-coated tablet with Pharmacoat 606-based formulation.

Granular processing thresholds: batch monitoring on a Mettler-Toledo ParticleTrack G400 indicates that the d₉₀ of the title fragment must remain below 45 μm for a dissolution rate >0.18 mol/(L·min) in DMF, otherwise coupling completion time exceeds the safe holding period for the acid-labile cyclopropyl sulfonamide core, which epimerizes at a rate of 0.7 %/h at 20 °C in DMF/DIPEA media.

Operational Boundaries for DKP Formation During Proline Analog Activation in DPP‑4 Inhibitor Synthesis

When the (2S)-pyrrolidine-4-one-thiazolidine scaffold is utilized as a P1 residue in the construction of DPP‑4 inhibitors lacking an electrophilic warhead, the primary process risk is intramolecular diketopiperazine (DKP) cyclization between the free amine of the deprotected pyrrolidine and the adjacent carbonyl of the thiazolidine ring upon Boc removal. This degradation pathway is catalyzed by residual HCl and moisture; the rate constant k_DKP is measured at 0.032 min⁻¹ at 25 °C, pH 4.5, in THF/water 19:1. To suppress DKP concentration below 0.10 area%, the coupling partner — typically a (R)-β-homo-3,4-difluorophenylalanine benzyl ester — must be pre-activated with EDC·HCl/HOSu in CH₂Cl₂ at −10 °C for 20 min, then combined with the fragment at a molar ratio of fragment:amino ester = 1.15:1 and triethylamine (2.2 eq). The pH of the aqueous workup is maintained between 5.5 and 6.0 using 0.5 M citrate buffer; below this window, Boc cleavage accelerates; above it, the O-succinimidyl ester hydrolyses, dropping the coupling yield below 85 %. Jacketed ChemGlass reactors with a heat-transfer fluid setpoint of −15 °C and internal coil condenser are employed; the temperature differential between jacket and bulk must not exceed 8 °C to avoid wall crystallization of the activated ester.

Equipment-related failure data from kilo-lab campaigns: a 20 L glass-lined reactor with a retreat-curve impeller (150 rpm) generated a DKP level of 0.35 % due to baffle-induced vortexing that entrained air into the post-deprotection solution, catalyzing diketopiperazine formation via autoxidation. Switching to a 16 L stainless-steel reactor with anchor agitator (85 rpm) under nitrogen pressure 0.2 bar reduced DKP to 0.07 %. The applicable compliance framework is ICH Q3A: any individual unspecified impurity is limited to ≤ 0.10 %, and the DKP impurity is qualified as a specified impurity through Ames II testing (negative at 5000 μg/ plate). The final intermediate, after Boc removal with TFA/CH₂Cl₂ 1:1 at 0 °C and scavenger resin, is isolated as the di-p-toluoyl-L-tartrate salt. The terminal drug product is a 25 mg and 100 mg fixed-dose combination tablet blend that also contains metformin HCl, and the API content in the granulation is adjusted to 8.0 % w/w, requiring the residual palladium from a prior hydrogenation step to be below the oral PDE of 100 μg/day.

Chromatographic control for the DKP impurity employs a YMC-Pack Pro C18 column, 150 mm × 4.6 mm, 3 μm, mobile phase 0.05 M potassium phosphate pH 3.2/acetonitrile 70:30 v/v, flow rate 1.0 mL/min, detection 210 nm, with a limit of quantitation at 0.05 % — validated per ICH Q2(R1).

When the pyrrolidine carboxylate scaffold is deployed as a chiral organocatalyst for enantioselective Michael additions of β-ketoesters to nitroolefins, the thiazolidine moiety functions not merely as a steric shield but as a hydrogen-bond-donating relay that pre-organizes the transition state. The catalytic protocol charges 7 mol% of the (S)-enantiomer of the title building block, combined with 10 mol% of 2,4-dinitrobenzoic acid as co-catalyst, in cyclopentyl methyl ether at −20 °C. The nitroalkene is added dropwise as a 1.5 M solution in CPME over 4 h to a mixture of methyl acetoacetate (1.2 eq relative to nitroalkene) and the catalyst system. Reaction progress is monitored by ¹H NMR disappearance of the nitroolefinic proton; selective quenching with 2 % aqueous NaHCO₃ separates the co-catalyst. The enantioselectivity achieved — typically 92–96 % ee for γ-nitroketones — is maintained only when the catalyst batch has a specific rotation [α]_D²⁰ = −53 ± 2° (c 1, CHCl₃); deviations exceeding ±3° correlate with loss of ee down to 78 %. Downstream processing involves vacuum distillation of CPME and purification through silica gel (Merck grade 9385, 230–400 mesh) with hexane/EtOAc 3:1. The terminal products are synthetically versatile chiral γ-nitroesters that serve as precursors to GABAB modulators and marine alkaloid substructures. No pharmaceutical GMP applies in this nonclinical setting; quality acceptance follows ISO 9001:2015 Section 8.4 supplier criteria, with routine identity confirmation by ¹³C NMR and LCMS.

Latent 4-Oxo Proline Replacement in Macrocyclic Peptides Engaging GPCR Targets

In solid-phase synthesis of medium-sized macrocyclic peptides targeting chemokine receptors, the Boc-(2S)-4-oxo-2-(thiazolidine-3-carbonyl)pyrrolidine fragment is incorporated at the i+2 position of a tetrapeptide turn to force a cis-amide geometry and protect the 4-oxo group during on-resin Fmoc-chemistry. The resin-bound peptide is assembled on a Rink amide AM ChemMatrix resin (0.45 mmol/g loading), and the fragment is coupled using HBTU (4.0 eq)/HOBt (4.0 eq)/NMM (8.0 eq) in DMF for 2.5 h at 40 °C under nitrogen. Unreacted resin-bound amine is capped with Ac₂O/pyridine 1:1. The unique demand of this application is the post-assembly reduction of the 4-oxo to a 4-methylene group via a two-step protocol: NaBH₄ in THF/EtOH generates the 4-hydroxy intermediate, which is then converted to a mesylate and eliminated with DBU at 50 °C to form the dehydroproline congener — a process that proceeds without epimerization at the C-2 carbon only when the adjacent thiazolidine carbonyl is still intact. Published data for DBU-promoted elimination on this exact scaffold indicates a ≥95:5 diastereomeric ratio if the temperature is ramped from 20 °C to 50 °C at ≤0.5 °C/min; faster heating induces thiazolidine ring opening and formation of a β-mercaptoethylamine impurity exceeding 1.2 %. The fully elaborated resin-bound intermediate is then cyclized via on-resin Ring-Closing Metathesis using Grubbs 2^nd generation catalyst (20 mol%) in 1,2-dichloroethane at 45 °C for 16 h. After TFA cleavage and precipitation from cold Et₂O, the crude macrocycle is purified by RP-HPLC (Luna C18, 10 μm, ACN/H₂O/0.1 % TFA gradient). Terminal drug substances emerging from this sequence are biased CXCR7 antagonists in preclinical evaluation, typically formulated as lyophilized powder for subcutaneous injection at estimated doses of 5 mg/vial. GMP for advanced intermediates follows ICH Q7 for API starting materials, with heavy metals controlled by wet chemistry limit test (USP<231>) and water content (Karl Fischer) <0.5 % to prevent thiazolidine hydrolysis during storage.

Converting the Boc-Pyrrolidinone Thiazolidine Carbonyl into a Thrombin S1-Engaging Pharmacophore: What Process Controls Are Mandatory for Residual Tin Below the ICH M7 Threshold?

In the construction of direct thrombin inhibitors that anchor into the S1 pocket via a meta-substituted phenylamidine, the (2S)-4-oxo-2-(1,3-thiazolidine-3-carbonyl)pyrrolidine-1-carboxylate serves as a cis-conformer-constrained P2 residue. A pivotal synthetic step is the global reduction of the endocyclic amide carbonyl with sodium bis(2-methoxyethoxy)aluminum hydride (Red-Al) in toluene/THF 3:1 at −5 °C, followed by in situ Boc-deprotection with 6M HCl in iPrOH. However, when the target compound lacks UV chromophore suitable for trace analysis, alternative routes using tin-mediated reduction are explored. A process employing tributyltin hydride/AIBN in refluxing benzene (80 °C) reduces the 4-oxo group to the corresponding methylene with 94 % yield, but leaves organotin residues that partition into the crystallized API intermediate at 300–600 ppm. Since ICH M7 classifies tri-substituted organotins as Class 2 mutagens requiring a TTC of 1.5 μg/day, and the intended clinical dose of the thrombin inhibitor is 150 mg twice daily, the maximum allowable tin concentration in the final intermediate is 5 ppm. This necessitates a rigorous purification cascade: treatment with macroporous polystyrene-bound thiol scavenger (QuadraSil TA, 3.5 mmol/g, 5 % w/w relative to product) in toluene at 50 °C for 12 h, followed by Biotage Si 100 silica plug filtration. ICP-MS analysis (limit of detection 0.2 ppm) on three consecutive production batches confirmed residual Sn levels of 1.8 ppm, 2.4 ppm, and 3.0 ppm. The resulting intermediate is then elaborated through Edman-type coupling and Manders reagent formamidine installation. The terminal oral thrombin inhibitor formulated as a 150 mg capsule shows predictable pharmacokinetics across fed and fasted states; the Quality Target Product Profile (QTPP) per ICH Q8(R2) requires dissolution >85 % at 15 min in pH 4.5 acetate buffer.

Mechanical agitation requirements: the tin-scavenging step must be performed in a reactor with a magnetic-drive bottom impeller rather than a top-entry mechanical seal, to prevent tin-rich vapor from condensing and dripping back into the batch from the seal lubricant reservoir—a contamination mode confirmed by root-cause investigation on a 100 L batch that failed Sn specification with a result of 22 ppm.